Genomics testing company Myriad Genetics is building on its growing momentum in the marketplace with a positive policy decision from UnitedHealthcare for its pharmacogenomic test for depression. Salt Lake City-based Myriad Genetics’ GeneSight screening analyzes specific genes as a way to predict the effectiveness of 56 common medications for depression. The information can be used by clinicians to more effectively target treatments to help ease symptoms.
UnitedHealthcare made its decision on the back of the company’s recently published GUIDED study which found that the GeneSight test was able to drive improvements in remission among individuals with depression who have failed at least one medication trial. The limited positive clinical results have been enough to make health care sponsors like Kroger and UnitedHealthcare to cover the test.
The coverage decision by UnitedHealthcare fits into a growing focus among payers on mental health as a contributor to worse overall health outcomes and a barrier to receiving care. Health economics research from UnitedHealth Group subsidiary OptumInsight found that GeneInsight was able to help drive more than $6,000 in savings in first year health care costs compared to treatment-as-usual for consumers with depression. The company also cites prior research showing clinicians using GeneInsight’s results to drive fewer disability claims and medical absence days.
UnitedHealthcare, part of the UnitedHealth Group family of businesses, is working to create a system that is connected, aligned, and more affordable for all involved; one that delivers high quality care, responsive to the needs of each person, and the communities in which they live. With connections to more than 1.3 million physicians and care professionals, and 6,200+ hospitals and care facilities across the globe, UnitedHealthcare can collaborate in new ways to improve consumer care while providing customizable and comprehensive solutions in any market place, anywhere.
Myriad Genetics, Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming consumer lives worldwide with pioneering molecular diagnostics. Myriad Genetics, Inc. discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve consumer care and lower health care costs. Myriad Genetics, Inc. is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products, and increasing the revenue contribution from international markets.
This was reported by Medcity News on August 1, 2019.
Contact information: UnitedHealthcare, 9700 Healthcare Lane, Minnetonka, Minnesota 55343; 763-797-2919; Website: www.uhc.com
Contact information: Myriad Genetics, Inc., 320 Wakara Way, Salt Lake City, Utah 84108; 800-469-7423; Website: www.myriad.com